About Neurogenic differentiation factor 2
Neurogenic differentiation factor 2 (NEUROD2) is a protein
from Homo sapiens identified by UniProt accession
Q15784, 382 residues long.
MolForge cross-references it against 0 known binders and
218 disease associations.
Target properties
| Protein name | Neurogenic differentiation factor 2 |
| UniProt accession | Q15784 |
| Gene | NEUROD2 |
| Organism | Homo sapiens |
| Length | 382 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (218)
Diseases linked to this target (Open Targets).
- developmental and epileptic encephalopathy · score 0.58
- neurodegenerative disease · score 0.32
- erythrocyte count · score 0.26
- red blood cell density measurement · score 0.22
- genetic disorder · score 0.19
- self reported educational attainment · score 0.12
- refractive error · score 0.10
- hematocrit · score 0.08
- mathematical ability · score 0.07
- Adult-onset autosomal recessive cerebellar ataxia · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15784-F1 | alphafold | PREDICTED | 60.07 | — |
Amino-acid sequence (382 residues)
MLTRLFSEPG LLSDVPKFAS WGDGEDDEPR SDKGDAPPPP PPAPGPGAPG PARAAKPVPL RGEEGTEATL AEVKEEGELG GEEEEEEEEE EGLDEAEGER PKKRGPKKRK MTKARLERSK LRRQKANARE RNRMHDLNAA LDNLRKVVPC YSKTQKLSKI ETLRLAKNYI WALSEILRSG KRPDLVSYVQ TLCKGLSQPT TNLVAGCLQL NSRNFLTEQG ADGAGRFHGS GGPFAMHPYP YPCSRLAGAQ CQAAGGLGGG AAHALRTHGY CAAYETLYAA AGGGGASPDY NSSEYEGPLS PPLCLNGNFS LKQDSSPDHE KSYHYSMHYS ALPGSRPTGH GLVFGSSAVR GGVHSENLLS YDMHLHHDRG PMYEELNAFF HN
Explore Neurogenic differentiation factor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets